Scientists present the largest-to-date genetic snapshot of Iceland 1000 years ago

19-Jan-2009 - Scientists at deCODE genetics have completed the largest study of ancient DNA from a single population ever undertaken. Analyzing mitochondrial DNA, which is passed from mother to offspring, from 68 skeletal remains, the study provides a detailed look at how a contemporary population differs from ...

deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer

Latest discoveries add to understanding of individual risk of basal cell carcinoma, and are integrated into the deCODEme™ personal genome analysis scan

15-Oct-2008 - Scientists at deCODE genetics reported the discovery of common versions of two single-letter variations in the human genome (SNPs) that confer risk of basal cell carcinoma (BCC). Unlike the four sets of SNPs previously found by deCODE to confer risk of BCC and cutaneous melanoma, those are not ...

A Smoking Gene: deCODE Shows How a Single Variant in the Sequence of the Genome Confers Nicotine Dependence

09-Apr-2008 - Cigarette smoking is a major public health problem that contributes to millions of deaths around the world each year. While the health risks of smoking are well known, relatively little is known about why some people are particularly likely to get addicted to cigarettes and may consequently be at ...

deCODE Announces Appointment of Peter Goodfellow to Board of Directors

15-Sep-2006 - deCODE genetics announced that it has named Dr. Peter Goodfellow to its Board of Directors, effective immediately. Dr. Goodfellow was until recently Senior Vice President for Discovery Research at GlaxoSmithKline, a position he held for the past six years. Prior to this post, he held senior ...

deCODE Initiates Phase III Trial for DG031 for the Prevention of Heart Attack

Pioneering use of human genetics to target the causative biology

19-May-2006 - deCODE genetics announced the initiation of patient enrollment in the pivotal Phase III trial for DG031, deCODE's lead developmental compound for the prevention of heart attack. The multicenter Phase III trial will be randomized, double-blind, placebo-controlled, and will enroll 3400 patients ...

deCODE and Illumina Form Alliance to Develop and Commercialize DNA-based Diagnostics

Companies to initiate work on molecular diagnostics for the risk of heart attack, type 2 diabetes and breast cancer

17-May-2006 - deCODE genetics and Illumina, Inc. announced the formation of a strategic alliance under which the companies plan to co-develop and commercialize DNA-based diagnostic tests in several major disease areas. The alliance will employ Illumina's platform for high-multiplex single-nucleotide ...

deCODE Successfully Completes Phase I Clinical Program for DG041 for the Treatment of Peripheral Artery Disease

24-Feb-2006 - deCODE genetics announced top-line results from Phase I clinical studies of DG041, the company's developmental compound for the treatment of peripheral artery disease (PAD). The company has completed the Phase I studies of DG041 and expects to begin a Phase II clinical trial before ...

deCODE Expands Cancer Program through Acquisition of Icelandic Cancer Research Group

20-Jan-2006 - deCODE genetics announced its acquisition of privately-held Icelandic cancer research firm Urdur, Verdandi Skuld (UVS). The acquisition enables deCODE to broaden and enhance its cancer program by applying the company's unique gene discovery and drug development capabilities to an even larger set ...

deCODE Discovers Major Genetic Risk Factor for Type 2 Diabetes

Discovery may enable development of diagnostics and drugs of major benefit to public health

17-Jan-2006 - A team of scientists from deCODE genetics and colleagues report the discovery of a variant in a gene on chromosome 10 that represents the most significant genetic risk factor for type 2 diabetes (T2D) found to date. More than one third of individuals in the populations studied carry one copy of ...

deCODE Announces Departure of Jean-Francois Formela from Board of Directors

02-Jan-2006 - deCODE genetics announced that Jean-Francois Formela left the company's Board of Directors, December 30th. Dr. Formela, a Senior Partner at Atlas Venture, has served on deCODE's board since the formation of the company in 1996 and plans to devote his time to a new Atlas fund. "Jean-Francois has ...